A long-held goal in oncology has been to develop therapies that target specific tumor abnormalities rather than treating cancers based solely on tissue of origin. In the past decade, advances in ...

Breast cancer pathogenesis is influenced by various molecular and environmental risk factors. It begins through the mutation of oncogenes, tumor suppressor genes, and dysregulation of key cell ...

The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET ...

Spinal metastasis, the spread of cancer to the spine, is a frequent complication in advanced cancer. It often causes severe ...

Real-world adoption of adjuvant molecularly targeted therapy and immunotherapy for resected stage Ib-III non-small cell lung cancer within the Veterans Health Administration. This is an ASCO Meeting ...

Reston, VA (December 4, 2025)--A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a ...

The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from ...

Spinal metastasis, the spread of cancer to the spine, is a frequent complication in advanced cancer. It often causes severe ...

The Global Plexiform Neurofibroma Market centers on the treatment of plexiform neurofibromas, benign nerve sheath tumors linked to Neurofibromatosis Type 1 (NF1). These tumors cause significant ...